TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06191185

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BPB, No PIN
Description: Patient-level: standard communication from care team.~Clinic-level: A program of best practices will be implemented to improve team communication, optimize practice workflow, and identify and track patients with abnormal FIT results through colonoscopy completion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BPB, PIN
Description: Patient-level: The patient-facing evidence-based instructions, communication, and navigation part of the intervention will leverage the short messaging service (SMS) text messaging platform, HealthySMS.~Clinic-level: A program of best practices will be implemented to improve team communication, optimize practice workflow, and identify and track patients with abnormal FIT results through colonoscopy completion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No BPB, PIN
Description: Patient-level: The patient-facing evidence-based instructions, communication, and navigation part of the intervention will leverage the SMS text messaging platform, HealthySMS.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No BPB, No PIN
Description: Patient-level: standard communication from their care team.
Study: NCT04671160

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment the activity of anti-Xa factor.
Description: Assessment the activity of anti-Xa factor in patients treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis, patients treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis, patients not treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis and patients not treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment the activity of anti-Xa factor.
Description: Assessment the activity of anti-Xa factor in patients treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis, patients treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis, patients not treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis and patients not treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment the activity of anti-Xa factor.
Description: Assessment the activity of anti-Xa factor in patients treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis, patients treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis, patients not treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis and patients not treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment the activity of anti-Xa factor.
Description: Assessment the activity of anti-Xa factor in patients treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis, patients treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis, patients not treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis and patients not treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis.
Study: NCT05348707

Intervention type: OTHER
Intervention: epidemiology
Description: To review medical records to describe diagnosis and severity of the disease.

Intervention type: OTHER
Intervention: epidemiology
Description: To review medical records to describe diagnosis and severity of the disease.

Intervention type: OTHER
Intervention: epidemiology
Description: To review medical records to describe diagnosis and severity of the disease.

Intervention type: OTHER
Intervention: epidemiology
Description: To compare pre and per Covid-19 epidemics in terms of numbers of admissions and proportion of severe disease.

Intervention type: OTHER
Intervention: epidemiology
Description: To compare pre and per Covid-19 epidemics in terms of numbers of admissions and proportion of severe disease.

Intervention type: OTHER
Intervention: epidemiology
Description: To compare pre and per Covid-19 epidemics in terms of numbers of admissions and proportion of severe disease.
Study: NCT04363294

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PYP scan
Description: 99mTc-labeled pyrophosphate
Study: NCT05677984

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Awaken prone positioning ventilation
Description: patients were mandated to keep a prone position for at least 12 hours.
Study: NCT04695093

Intervention type: OTHER
Intervention: Ultra Low Emission Zone (ULEZ)
Description: The ULEZ comprises a Central London zone, implemented on 8th April 2019, within which polluting vehicles are subject to a charge. Using number plate recognition technology, a daily penalty charge notice is issued for vehicles entering this central zone not meeting the standard of Euro 4 for petrol, Euro 6/VI for diesel, and Euro for motorcycles.~The ULEZ will subsequently be extended to include:~1. In 2020, a London-wide ULEZ for heavy duty vehicles (HDV) within the LEZ boundary (green zone). HDVs not meeting Euro 6 standard will be charged daily.~2. In 2021, an Inner London ULEZ area for all light duty vehicles (LDV) within the boundary of the North and South Circular Roads (yellow zone). Vehicles not meeting the above criteria will be charged daily as for the Central London area.
Study: NCT05951322

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave therapy
Description: Radial extracorporeal shock wave device, it is serial number (1107394), medispec and connected to electrical supply 115/220 A C frequency.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phonophoresis
Description: Pagani ultrasound apparatus 200 cosistts of multi frequency head(1 and 3 MHz), surface area 4 cm², continuous and pulsed mode, main voltages: 100-240-VAC.50/60Hz.
Study: NCT05888662

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endo-epicardial ablation
Description: Endo-epicardial ablation of ventricular tachycardia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endocardial ablation only
Description: endocardial-only catheter ablation of ventricular tachycardia
Study: NCT05799638

Intervention type: OTHER
Intervention: Guideline-Directed Medication Treatment (GDMT)
Description: GDMT contains ACEIs/ARBs/ARNI, β blockers, SGLT2is, MRAs. ACEI/ARB/ARNI and β blocker will gradually be titrated up to the maximum tolerable dose
Study: NCT04939480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg intravenous solution
Study: NCT04088981

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: Low-fat, plant-based diet and a portion-controlled diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: Low-fat, plant-based diet and a portion-controlled diet
Study: NCT05724186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test myopia control lenses (CSL)
Description: A pair of myopia control spectacle lenses (test lenses) will be given to subjects to wear for 12 months
Study: NCT05778305

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: a central sympatholytic drug

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: saline is given to control group
Study: NCT04798781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telatinib
Description: 900mg by mouth twice daily until disease progression, intolerable toxicities, or withdrawal of consent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keytruda
Description: 200mg intravenous infusion every three weeks until disease progression, intolerable toxicities, or withdrawal of consent
Study: NCT06442436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Description: 25 mg nemtabrutinib (1 x 5 mg and 1 x 20 mg tablets) administered orally as a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Description: 25 mg nemtabrutinib (1 x 5 mg and 1 x 20 mg tablets) administered orally as a single dose.
Study: NCT05160922

Intervention type: DRUG
Group type: OTHER
Intervention: crizotinib
Description: crizotinib oral treatment
Study: NCT06636617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.70 GBq (100 mCi) of 177Lu-JH04
Description: All 3 patients were intravenous injected with single dose 3.70 GBq (100 mCi) of 177Lu-JH04.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5.55 GBq (150 mCi) of 177Lu-JH04
Description: All 3 patients were intravenous injected with single 5.55 GBq (150 mCi) of 177Lu-JH04

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7.40 GBq (200 mCi) of 177Lu-JH04
Description: All 3 patients were intravenous injected with single 7.40 GBq (200 mCi) of 177Lu-JH04
Study: NCT06635252

Intervention type: DRUG
Intervention: STA 4783
Description: Use of statins will be identified from Prescribed Drug register within 6 months before dementia diagnosis or each follow-up date
Study: NCT06635564

Intervention type: DIAGNOSTIC_TEST
Intervention: Viscoelastic testing
Description: viscoelasting testing refers to a global hemostatic assay,that quantifies the viscoelastic properties of citrated whole blood

Intervention type: DIAGNOSTIC_TEST
Intervention: Viscoelastic testing
Description: viscoelasting testing refers to a global hemostatic assay,that quantifies the viscoelastic properties of citrated whole blood

Intervention type: DIAGNOSTIC_TEST
Intervention: Viscoelastic testing
Description: viscoelasting testing refers to a global hemostatic assay,that quantifies the viscoelastic properties of citrated whole blood
Study: NCT05234944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Type 1 Diabetes and Life
Description: Brief behavioral intervention, delivered remotely by certified diabetes care and education specialists, targeting diabetes-specific health-related quality of life for people with type 1 diabetes across the lifespan and for their parents and partners.
Study: NCT05582434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene Gel
Description: Single topical treatment arm topical to be applied daily to area affected

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene Gel and the clindamycin phosphate/benzoyl peroxide gel
Description: Two topical treatments will be dispensed and instructions to apply daily to affected area

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adapalene, benzoyl peroxide gel, and clindamycin phosphate gel every day.
Description: Three topical treatments will be dispensed and instructions to apply daily to affected area arm.
Study: NCT06525181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Generative Artificial Intelligence
Description: Gen AI assisted symptom intake summarization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard weekly symptom intake
Description: Standard weekly symptom intake performed by a physician
Study: NCT05505708

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxyethyl starch in sodium chloride injection Brand Name: Voluven
Description: (6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection) is a clear to slightly opalescent, colorless to slightly yellow, sterile, non-pyrogenic, isotonic solution for intravenous administration using sterile equipment.~Each 100 mL of the solution contains: 6 g of Hydroxyethyl Starch 130/0.4 and 900 mg of Sodium Chloride USP in Water for Injection USP.~In addition, sodium hydroxide, USP, or Hydrochloric acid, USP, has been added to adjust the final pH so the final solution pH is 4.0 to 5.5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline solution
Description: Within each 100 mL of 0.9% sodium chloride Injection USP, there is 15.4 mEq of sodium ions and 15.4 mEq of chloride ions. Additionally, the osmolarity is 308 mOsmol/liter, and it has a pH range of 4.5 to 7
Study: NCT05469503

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TOTUM-854
Description: 12 weeks of TOTUM-854 supplementation
Study: NCT06329635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Nicardipine
Description: First, 6 ml of cerebrospinal fluid is withdrawn from the EVD or LD catheter, and then 4 ml (4mg) of nicardipine is injected into the EVD or LD drain tube, followed by 2 ml normal saline solution, and then the EVD or LD tube is clamped for 2 hours, and then kept open as clinically necessary until the next dose (q12h) of medication.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No intervention
Description: A simulated intrathecal administration operation is performed by a dedicated physician who is unblinded to the group assignment, the EVD or LD tube is not opened, and no drug is given. The simulated administration process needs to be out of the patient's view (if awake patient) and out of the presence of study team personnel.
Study: NCT05215574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGM831
Description: Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGM831 plus pembrolizumab (KEYTRUDA®)
Description: Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®) pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
Description: Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21-day cycle. Multiple dose levels will be evaluated.~Drug: NGM438 NGM438 is given intravenously (IV) every 3 weeks in a 21-day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®) pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21-day cycle.
Study: NCT05872139

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gelatin capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mitoquinone Mesylate
Description: MitoQ was given once (single dose, 80 mg)
Study: NCT05970393

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pressure support level tatrition
Description: Baseline ventilators were set by the principle of keeping VT/PBW at 6-8ml/kg and RR at 20-30 breaths/min and the decision of the responsible ICU physician. After then the fraction of inspired oxygen (FiO2), positive expiratory end pressure (PEEP), trigger sensitivity, and cycle-off criteria remain unchanged. Upward and downward PS level adjustments were performed from the baseline PS level at a 1cm H2O interval. Every PS level was maintained for 20 minutes and then three end-inspiratory holdings (2-3seconds) and three end-expiratory holdings were performed. PMI mean value was measured and calculated at every PS level. To avoid additional injury to the lung and diaphragm, the airway peak pressure (Ppeak) was limited to 30cmH2O, and titrating PS was stopped until PMI was less than -1cmH2O and more than 3cmH2O.The inspiratory effort is measured as the pressure generated by inspiratory muscles using esophageal pressure monitoring.
Study: NCT06111950

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: Blood samples of 5 ml to 15 ml depending on their weight

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: Blood samples of 5 ml to 15 ml depending on their weight
Study: NCT05938023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATL1102 25mg
Description: Dose and scheduled as specified in the Arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATL1102 50mg
Description: Dose and scheduled as specified in the Arm description
Study: NCT06721871

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Powder for Oral Solution
Description: Matching Placebo Powder for Oral Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Powder for Oral Solution
Description: Matching Placebo Powder for Oral Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Powder for Oral Solution
Description: Matching Placebo Powder for Oral Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Powder for Oral Solution
Description: Matching Placebo Powder for Oral Solution
Study: NCT06719622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: 1 mg budesonide ampoule twice daily for patients weighing ≤35 kg or 2 mg twice daily for patients weighing \>35 kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole (proton pump inhibitor)
Description: omeprazole 10 mg twice daily for patients weighing ≤35 kg or 20 mg twice daily for patients weighing \>35 kg
Study: NCT06111950

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: Blood samples of 5 ml to 15 ml depending on their weight

Intervention type: OTHER
Group type: OTHER
Intervention: Skin biopsies
Description: Biopsies of fragment of skin 2 to 3 mm long by 1 mm wide and 1 mm deep will preferably be taken on the inside of the arm, in the upper third, between the bend of the elbow and the hollow of the armpit under strict sterility conditions.
Study: NCT06720805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentabiocel
Description: This is a randomized, double-blind, placebo-controlled, multicenter clinical trial aimed at recruiting 56 pediatric patients with IBS.~The activities will be divided into the following phases:~1. Patient Enrollment Phase: eligible patients will meet the diagnostic criteria for IBS, as defined by internationally recognized guidelines. Informed consent will be obtained from the legal guardians of the participants before their inclusion in the study.~2. Randomization: the enrolled participants will be randomly assigned to one of two groups: the probiotic group or the placebo group.~3. Treatment Phase: a 3-month treatment phase will be conducted with a mixture of 5 strains of lactic acid bacteria and bifidobacter.~4. Follow-up Phase: this will be followed by a 4-week follow-up phase. Clinical data will be monitored throughout the study using validated questionnaires.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is a randomized, double-blind, placebo-controlled, multicenter clinical trial aimed at recruiting 56 pediatric patients with IBS.~The activities will be divided into the following phases:~1. Patient Enrollment Phase: eligible patients will meet the diagnostic criteria for IBS, as defined by internationally recognized guidelines. Informed consent will be obtained from the legal guardians of the participants before their inclusion in the study.~2. Randomization: the enrolled participants will be randomly assigned to one of two groups: the probiotic group or the placebo group.~3. Treatment Phase: a 3-month treatment phase will be conducted with a mixture of 5 strains of lactic acid bacteria and bifidobacter.~4. Follow-up Phase: this will be followed by a 4-week follow-up phase. Clinical data will be monitored throughout the study using validated questionnaires.
Study: NCT06720740

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RELIEF Ureteral Stent
Description: The study intervention is placement of the RELIEF Ureteral Stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Ureteral Stent
Description: The control product is the Ascerta stent by Boston Scientific.
Study: NCT06720402

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sun protection knowledge
Description: To increase knowledge and awareness about sun protection methods, a presentation will be implented to pediatricians and family physicians.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sun protection knowledge
Description: To increase knowledge and awareness about sun protection methods, a presentation will be implented to pediatricians and family physicians.
Study: NCT04944784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reldesemtiv
Description: Reldesemtiv Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reldesemtiv
Description: Reldesemtiv Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reldesemtiv
Description: Reldesemtiv Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Oral Tablet
Study: NCT05938023

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose and scheduled as specified in the Arm description
Study: NCT05023915

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: 40 mg qd for 4 days
Study: NCT05327725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatigue Reduction Diet
Description: Participants receive individualized nutrition counseling to adopt the fatigue reduction diet protocol.
Study: NCT06423183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Mindful Approach to Building a Resilient Healthcare Workforce (RENEW)
Description: Synchronous, 4-month intervention that teaches skills in mindfulness, stress management, and resilience as an individual and as a team. Sessions occur monthly and include a 1 hour in-person introductory session followed by 3 50-minute virtual sessions.
Study: NCT06111950

Intervention type: OTHER
Group type: OTHER
Intervention: Skin biopsies
Description: Biopsies of fragment of skin 2 to 3 mm long by 1 mm wide and 1 mm deep will preferably be taken on the inside of the arm, in the upper third, between the bend of the elbow and the hollow of the armpit under strict sterility conditions.

Intervention type: OTHER
Group type: OTHER
Intervention: Fetal samples
Description: Skin, muscle, brain and bone biopsies will be collected from fetuses in the autopsy room after the medical termination of pregnancy or miscarriage
Study: NCT05432583

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT163
Description: Anti-viral ribonucleic acid (RNA) vaccine for active immunization against HSV-2 administered as intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT163
Description: Anti-viral ribonucleic acid (RNA) vaccine for active immunization against HSV-2 administered as intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT163
Description: Anti-viral ribonucleic acid (RNA) vaccine for active immunization against HSV-2 administered as intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT163
Description: Anti-viral ribonucleic acid (RNA) vaccine for active immunization against HSV-2 administered as intramuscular injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06111950

Intervention type: OTHER
Group type: OTHER
Intervention: Fetal samples
Description: Skin, muscle, brain and bone biopsies will be collected from fetuses in the autopsy room after the medical termination of pregnancy or miscarriage